

Speaker Biographies

2023 Annual Meeting
American Cancer Society
National Lung Cancer Roundtable



December 4–5
Washington, D.C.

Pathways of Care: Focusing on the Patient Experience
Across the Lung Cancer Continuum



CONTENTS

Marissa Brown, MA.....	4
Mitchell Anderson.....	4
Smita Banerjee, PhD.....	5
Danell Boatman, EdD, MS.....	5
Ian Bostock, MD, MS.....	6
Marissa Brown, MA.....	6
Terri Ann DiJulio.....	7
Jill Feldman.....	7
Mark Fendrick, MD.....	8
Laurie Fenton Ambrose.....	9
Narjust Florez, MD.....	10
Adam Fox, MD.....	11
Nikki Hayes, MPH.....	13
Richard Hoffman, MD, MPH.....	13
Melinda Hsu, MD.....	14
Gregory C. Kane, MD, MACP.....	14
Ella A. Kazerooni, MD, MS, FACR, FSABI.....	15
Montessa Lee.....	16
Aurora Lucas.....	17
Timothy M. Merchant.....	17
Drew Moghanaki, MD, MPH.....	18
Michelle Mollica, PhD, MPH, RN, OCN.....	18
Ronald E. Myers, DSW, PhD, FSBM.....	19
Shreya Papneja.....	19
Manali Patel, MD, MPH, MS, FASCO.....	20
Estelamari Rodriguez, MD, MPH.....	20



NATIONAL
LUNG CANCER
ROUNDTABLE

2023 AM SPEAKER BIOGRAPHIES

Priyanka Senthil	21
Lecia V. Sequist, MD, MPH.....	21
Kathryn Taylor, PhD	22
Betty Tong, MD, MHS, MS	22
Thomas K. Varghese Jr. MD, MS, MBA, FACS, MAMSE	22
Richard Wender, MD.....	23
J. Lee Westmaas, PhD	24
Ignacio I. Wistuba, MD	24
Douglas E. Wood, MD, FACS, FRCSEd	25

Marissa Brown, MA



Marissa Brown, MA, is the Senior Vice President for State and Local Advocacy at the American Cancer Society, Cancer Action Network. In this role she is responsible for directing ACS CAN’s public policy advocacy across the US in addition to directing strategic planning and metrics. Prior to this role, she was the founding Executive Director at Democracy Initiative, a start-up organization energizing membership organizations on behalf of issues related to American democracy. She also served as Deputy Director of the Alliance for Justice and Vice President of Programs at League of Conservation Voters Education Fund. She earned her MA and BA from the Johns Hopkins University. She lives in Silver Spring, MD and reads extensively, enjoys long walks, craft beer and yoga.

Mitchell Anderson



Mitchell Anderson is from Draper, Utah and a third-year student at Brigham Young University and hopes to study at a medical school to eventually become a physician. Mitch serves as an intercollegiate director where he oversees 1/3 of the ALCSI college chapters and their activities. In his free time Mitch enjoys playing golf, snow skiing in Utah, and pickup basketball with his buddies.

Smita Banerjee, PhD



Smita Banerjee, PhD, is an Associate Attending Behavioral Scientist in the Department of Psychiatry and Behavioral Sciences at Memorial Sloan Kettering Cancer Center. Her research is in cancer prevention and control, with special emphasis on the role of communication between oncology care providers and patients, and message framing for cancer risk prevention. Her recent work has primarily been contextualized in the areas of communication skills training to (a) reduce stigma experienced by patients with lung cancer who smoke(d), (b) improve sexual and gender minority (SGM) sensitivity for oncology care providers, and (c) encourage oncology care providers to discuss sexual health concerns of cisgender female

patients with cancer. Dr. Banerjee’s research has been funded by the NCI, NIDA, and philanthropic organizations like T. J. Martell Foundation, Goldstein Foundation, and Geri & Me Foundation. Along with Dr. Jamie Ostroff, Dr. Banerjee is currently leading an NCI-funded national multisite trial of empathic communication skills training to reduce lung cancer stigma.

Danell Boatman, EdD, MS



Danell Boatman, EdD, MS, is an Assistant Professor in the West Virginia University School of Medicine, Department of Cancer Prevention and Control, where she has established an applied research portfolio that leverages communication science to reduce cancer health disparities in Appalachia. Her research focuses on healthcare communication, multilevel communication interventions, and social media/online ecosystems. Dr. Boatman is a subject matter expert in cancer communication science. She leads the Communicating for Health in Appalachia by Translating Science (CHATS) Lab with the goal of finding the best ways to communicate science with different audiences. Dr. Boatman is an experienced

public health evaluator and quality improvement practice facilitator in rural primary care. She was selected as a 2023 Putnam Scholar with the Academy of Communication in Healthcare and serves as a member of the Stigma and Nihilism Task Group with the National Lung Cancer Roundtable.

Ian Bostock, MD, MS



My name is **Ian C. Bostock Rosenzweig, MD, MS**, and I'm originally from Mexico City, Mexico. I have been fortunate enough to complete my training in General Surgery at Brigham and Women's Hospital at Harvard Medical School and Dartmouth Hitchcock Medical Center at Geisel School of Medicine. Subsequently, I pursued my fellowship training in Cardiothoracic Surgery at The University of Texas MD Anderson Cancer Center in Houston, TX with a specific focus in General Thoracic Surgery and Thoracic Oncology.

The patients that present with ailments that require the care of a Thoracic Surgeon are often frail, and not uncommonly, part of underserved populations. This is one of the reasons I was first attracted to this field, and I believe that with my training, I'm able to support the establishment of important prevention, diagnostic, and treatment initiatives at MUSC. My research efforts are focused in investigating the management of advanced stage lung cancer through a multidisciplinary approach and evidence-based interventions. I believe this work can help target specific groups that would benefit from quality improvement initiatives and provide better oncologic outcomes and optimal survival.

Marissa Brown, MA



Marissa Brown, MA is the Senior Vice President for State and Local Advocacy at the American Cancer Society, Cancer Action Network. In this role she is responsible for directing ACS CAN's public policy advocacy across the US in addition to directing strategic planning and metrics. Prior to this role, she was the founding Executive Director at Democracy Initiative, a start-up organization energizing membership organizations on behalf of issues related to American democracy. She also served as Deputy Director of the Alliance for Justice and Vice President of Programs at League of Conservation Voters Education Fund. She earned her MA and BA from The Johns Hopkins University. She lives in Silver Spring, MD and reads

extensively, enjoys long walks, craft beer and yoga.

Terri Ann DiJulio



Terri Ann DiJulio is a three-time lung cancer survivor, stroke survivor, and a member of a multigenerational lung cancer family. Terri Ann is a lung cancer patient advocate and activist who raises awareness as a writer and public speaker.

Jill Feldman



Jill Feldman is a lung cancer patient and advocate. With an extensive family history of lung cancer, Jill got involved in lung cancer advocacy in 2001, when it was in its infancy. In 2009, at 39 years old with four small children, Jill herself was diagnosed with EGFR positive lung cancer.

Jill is committed to understanding and promoting patient-centered research as past Chair of IASLC's patient advisory board, a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, a member of the ECOG-ACRIN Research Group's patient advocate committee and thoracic committee, and as the patient advocate on the National Lung Cancer Round Table steering committee. In addition, she is a co-founder of the EGFR Resisters, a grassroots, patient-driven community committed to accelerating research that will prolong and better the lives of people diagnosed with EGFRm lung cancer.

Jill serves in various other leadership roles to improve the speed and quality of research and use her voice and privilege to embed a health equity lens in all aspects of research and care.

Mark Fendrick, MD



A. Mark Fendrick, MD, is a Professor of Internal Medicine in the School of Medicine and a Professor of Health Management and Policy in the School of Public Health at the University of Michigan. Dr. Fendrick received a bachelor's degree in economics and chemistry from the University of Pennsylvania and his medical degree from Harvard Medical School. He completed his residency in internal medicine at the University of Pennsylvania where he was a fellow in the Robert Wood Johnson Foundation Clinical Scholars Program.

Dr. Fendrick conceptualized and coined the term Value-Based Insurance Design (V-BID) and currently directs the V-BID Center at the University of Michigan [www.vbidcenter.org], the leading advocate for development, implementation, and evaluation of innovative health benefit plans. His research focuses on how clinician payment and consumer engagement initiatives impact access to care, quality of care, and health care costs. Dr. Fendrick has authored over 350 articles and book chapters and has received numerous awards for the creation and implementation of value-based insurance design. His perspective and understanding of clinical and economic issues have fostered collaborations with numerous government agencies, health plans, professional societies, and health care companies.

Dr. Fendrick is an elected member of the National Academy of Medicine (formerly IOM), serves on the Medicare Coverage Advisory Committee, and has been invited to present testimony before the U.S. Senate Committee on Health, Education, Labor and Pensions, the U.S. House of Representatives Ways and Means Subcommittee on Health, and the U.S. Senate Committee on Armed Services Subcommittee on Personnel. Dr. Fendrick is the co-editor in chief of the American Journal of Managed Care and is an editorial board member for 3 additional peer-reviewed publications. He is also a member of the Institute for Healthcare Policy and Innovation at the University of Michigan, where he remains clinically active in the practice of general internal medicine.

Laurie Fenton Ambrose



Laurie Fenton Ambrose is a dynamic, innovative leader who has spent a lifetime in service following her passion for supporting those in need. She has dedicated the last 18 years to confronting lung cancer and transforming survivorship. As co-founder, president and CEO of GO2 for Lung Cancer, Laurie is responsible for setting and executing the organization’s overarching vision and mission, driving the creation and implementation of their core program areas including patient information and support services, patient-centered academic and community-based research, health policy agenda, national awareness, and excellence in healthcare delivery.

Laurie is GO2’s national spokesperson and primary liaison to community and government leaders, national media, collaborating agencies, health care professionals, and strategic alliances. Her strategic oversight of GO2 and these outside organizations has achieved national and international recognition for improving health policies and leading public awareness to shift the disease from one of stigma to one of hope.

Prior to GO2, Laurie served as president & CEO of the Lung Cancer Alliance. Her work in nonprofit was preceded by nearly two in decades in public policy having served as Chief of Staff to United States Department of Commerce Secretary Don Evans and Senator Jon Kyl (R-AZ). She also served 11 years in the House of Representatives, six years as Chief of Staff to Congressman Jim Kolbe (R-AZ), and 5 years as Legislative Assistant to Congressmen Amo Houghton (R-NY) and Edward Madigan (R-IL).

Narjust Florez, MD



Dr. Narjust Florez, MD, is originally from Venezuela, she graduated first in her medical school class at the Universidad Catolica Nordestana in the Dominican Republic. She completed her internal medicine residency at Rutgers New Jersey Medical School (selected as the most scholarly resident in the Department of Medicine in 2015 and 2016) and fellowship at the Mayo Clinic in Rochester, Minnesota, where she was Chief Fellow from 2018 -2019.

She is a thoracic medical oncologist and the Associate Director of The Cancer Care Equity Program at Dana-Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School. In

2022, Dr. Florez also became the first Latina to hold an Associate Editor position in Oncology as the new Associate Editor for Diversity, Equity, and Inclusion at *JAMA Oncology*.

Dr. Florez's clinical interests include targeted therapy for lung cancer and the care of women and young patients with lung cancer, including their unique aspects of cancer survivorship. She is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study, the largest study to date evaluating sexual dysfunction in women with lung cancer. Additionally, she is also the principal investigator on other notable studies, including the Fertility and Sexual Health Effects of Immune Checkpoint Inhibitors on young women with Non-small Cell Lung Cancer and Melanoma (FhINCH) Study, The Diagnostic Delays in Lung Cancer (LEAD) Study, and the Young Lung Cancer (YLC) Study, which evaluates the psychosocial needs of young patients with lung cancer.

Apart from her clinical interests in lung cancer, she is also a globally acclaimed and highly productive researcher in cancer health disparities, gender and racial discrimination in medical education and medical practice. Dr. Florez is one of the co-founders of the Twitter community #LatinasInMedicine, now composed of about 10,000 members globally. She has received many awards, including the first-ever Mayo Clinic Diversity and Inclusion Champion Award in 2017, the 2018 Resident of the Year Award by the National Hispanic Medical Association, the 2018 Minority Scholar in Cancer Research Award by American Association of Cancer Research, the 2019 Mayo Brothers Distinguished Fellowship Award, the 2020 Rising Star Award by LEAD National Conference for Women in Hematology and Oncology, the 2021 International Association for the Study of Lung Cancer (IASLC) North America Cancer Care Team Award for Outstanding Clinical Care. More recently, she received the 2023 Career Development Award in Racial and/or Ethnic Disparities by the American Society of Clinical Oncology (ASCO), and the 2023 Medical Marvel Award by *Newsweek*.

In addition, Dr. Florez founded the Florez Lab in 2019. The laboratory focuses on lung cancer, social justice issues in medicine, and medical education. The laboratory's long-term goals are to create a

welcoming environment for medical trainees from historically underrepresented groups in medicine while improving the care of vulnerable populations. Members of the Florez Lab are agents of change. Since its foundation, the Florez laboratory has received research funding from several national agencies and published over 50 original studies and editorials.

Dr. Florez has over 115 scientific publications and her work has been published in high impact journals such as the *Journal of Clinical Oncology*, *Nature*, *Cancer Cell*, *JAMA Oncology* and *Lancet Oncology*. In 2021, she was awarded the Most Highly Cited Author Award by *The Mayo Clinic Proceedings*. Her work has been featured in various media outlets including *The New York Times*, *STAT News*, *Healio*, *OncoLive*, *Vox News*, *Business Insider*, *ASCO Post*, *ASCO Connection*, *Doximity*, and *The Cancer Letter*. Twitter: @NarjustFlorezMD

Adam Fox, MD



I am a pulmonologist and clinician scientist with a research focus in health services research for patients with lung cancer at the Medical University of South Carolina (MUSC). My long-term research goal is to improve care delivery for patients newly diagnosed with lung cancer, especially as it relates to precision medicine therapies. My clinical time is spent evaluating patients suspected to have lung cancer in a multi-disciplinary thoracic oncology clinic, performing bronchoscopy for diagnostic or staging purposes, and collaborating on cases through our multi-disciplinary thoracic tumor board. Biomarker testing performed on patient's lung cancer tissue continues to grow in importance in driving precision medicine treatment decisions,

especially as new therapies and indications emerge for both targeted and immune therapies. I witness, first-hand, many issues surrounding obtaining tissue and accomplishing biomarker testing for patients newly diagnosed with lung cancer. These issues span the spectrum from obtaining enough tissue for testing, choosing which assays to use to perform testing, coordination across subspecialties, gaps in knowledge and values by physicians to perform testing, and navigating these issues to achieve timely and comprehensive results. Motivated by the needs of patients, I became interested in the responsibility of pulmonologists and other sub-specialists to achieve timely and comprehensive biomarker testing for patients with lung cancer.

I serve as co-principal investigator on a grant from the American Cancer Society (ACS) to assess biomarker testing and treatment patterns in nationally representative databases. I am the co-lead faculty for the ACS Extension for Community Health Outcomes (ECHO) for biomarker testing in South Carolina, and I am a member of the ACS National Lung Cancer Roundtable (NLCRT) Triage for Appropriate Treatment Task Group. In collaboration with the NLCRT, I have worked on projects advancing biomarker testing in non-small cell lung cancer (NSCLC) including publishing the group's

Strategic Plan for Advancing Biomarker Testing in NSCLC, which is in press at Cancer, and another manuscript that reviews best practices in obtaining tissue for biomarker testing, published in CA: A Cancer Journal for Clinicians. I have also published results of a survey describing knowledge and practices of pulmonologists in obtaining biomarker testing. Finally, I made significant contributions to a manuscript proposing quality benchmarks for testing and recommendations to improve turnaround time, in press at Cancer. I am also leading local efforts within my institution to improve biomarker testing practices. I have also served as Faculty for the Association of Community Cancer Center's Evolving Biomarkers in NSCLC program.

My short-term developmental goal during the ACS Clinician Scientist Development Grant is to advance my research skills and training to become an independent investigator. The projects and training plan detailed in this proposal are poised to advance specific research skills in the realms of qualitative analysis, clinical research study design, implementation science, and health informatics. Additionally, the proposed work will provide evidence for future grant funding to investigate interventions to provide lung cancer patients with optimal treatment options.

Since the last submission, I have been promoted to Assistant Professor and have advanced my research training and program, with one manuscript now in-print and another manuscript accepted. I have several additional manuscripts that I am progressing towards publication. I am currently working to publish results of a completed cross-sectional survey describing attitudes and practices of community pulmonologists for biomarker testing. I am finalizing variable selection for analyses in a nationally representative cancer registry and Medicare claims database for outcomes related to lung cancer biomarker testing. I anticipate at least 3 manuscripts from these analyses. Another manuscript will describe ordering delays from a large database, highlighting the need for more interventions to improve this critical but under-appreciated and understudied step in biomarker testing. Finally, I have submitted an invited review describing best practices for biomarker testing specifically written for pulmonologists in the journal CHEST.

Nikki Hayes, MPH




Nikki Hayes, MPH, has been with the CDC’s Division of Cancer Prevention and Control (DCPC) in the agency’s National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) since 2002. Before joining CDC, she was a Biologist in the National Institute of Dental and Craniofacial Research (NIDCR) at the National Institutes of Health (NIH), where she established and managed the Institute’s DNA Sequencing Core Facility for more than 10 years. Nikki is currently the Chief of the DCPC Comprehensive Cancer Control Branch and is responsible for the successful implementation of one of the agency’s flagship, multi-million-dollar, cancer prevention and control programs, the National Comprehensive Cancer Control Program (NCCCP). She also manages several other programs that focus on improving the quality of life of cancer survivors, particularly young breast cancer survivors and metastatic breast cancer patients; and advancing commercial tobacco use prevention and cancer prevention in populations experiencing tobacco- and cancer-related health disparities. Nikki has published a number of peer-reviewed manuscripts and presented to national audiences on topics that include disparities in cancer-health outcomes; increasing population-based cancer screening; cancer control planning and implementation; and COVID-19 incidence in disparate populations.

Richard Hoffman, MD, MPH



Richard Hoffman, MD, MPH is an Emeritus Professor of Medicine at the University of Iowa Carver College of Medicine. He was formerly the Director, Division of General Internal Medicine and the Co-leader of the Cancer Epidemiology and Population Science Program at the Holden Comprehensive Cancer Center. He is a member of the NLCRT Shared Decision Making Task Group and a member of the American Cancer Society’s Guideline Development Group. He has a strong clinical and research interest in cancer screening.

Melinda Hsu, MD



Melinda (Mindy) Hsu, MD, is a thoracic medical oncologist at University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center and an Assistant Professor of Medicine at Case Western Reserve University, specializing in the care of patients with lung cancer, mesothelioma, and thymoma. She is an active researcher in the field of lung cancer survivorship. She is also the Director of Cancer Survivorship at University Hospitals Seidman Cancer Center, where she is expanding their survivorship program across all solid tumors and hematologic malignancies. Prior to a career in medicine, she studied developmental psychology and received her undergraduate degree at Harvard University, followed by a Masters in Science in

Physiology with specialization in Complementary and Alternative Medicine at Georgetown University. During her subsequent career at Procter and Gamble in Cincinnati, she decided to pursue medical school at the University of Cincinnati College of Medicine. This was followed by an internal medicine residency and chief resident year at Indiana University, and the medical oncology fellowship at Johns Hopkins University.

Gregory C. Kane, MD, MACP



Gregory C. Kane, M.D., MACP, is the Jane and Leonard Korman Professor and Chair of the Department of Medicine at Jefferson Health in Philadelphia, a position he has held since 2011. For fourteen years he served as Program Director of the Internal Medicine Residency at Sidney Kimmel Medical College/Jefferson University Hospital and he served as Interim Division Director of Pulmonary/Critical Care from 2008 through 2010.

A national leader in the fields of Pulmonary Medicine, Critical Care, and Medical Education, Dr. Kane has been active with the American Board of Internal Medicine (ABIM) on the Critical Care Test and Policy Committee (1996-2006) and the ABIM Hospitalist Medicine Test Committee helping develop the very first examination for recertification in Hospital Medicine. He was elected to a three-year term on the Council of the Association of Program Directors in Internal Medicine (APDIM) in 2006 and served as Association's President in 2013. He has also served as Treasurer of the Alliance for Academic Internal Medicine; the leading organization of academic physicians nationally representing Chairs of Medicine, Program Directors, Clerkship Directors, Sub-specialty Professors, and Administrators within Departments of Medicine. Dr. Kane is a former Governor of the American College of

Physicians, representing Pennsylvania. In 2019, he was elected Treasurer of the ACP for a 3-year term as a volunteer leader of the American College of Physicians, the largest single specialty medical society in the U.S. Dr. Kane has authored more than 100 original articles which have appeared in *Academic Medicine*, *Annals of Internal Medicine*, *American Journal of Respiratory and Critical Care Medicine*, *Chest*, *Respiratory Medicine*, *JAMA Open Network*, *Lung Cancer* and the *American Journal of Medicine*. His published work spans a broad diversity of clinical and medical education topics including lung cancer, lung cancer screening, pulmonary embolism, asthma, social determinants of health physician workforce and graduate medical education policy. Dr. Kane's most recent book was entitled *Lung Cancer Screening, A population approach* was authored with colleagues at Jefferson and across the country. The volume serves as a resource for programs wishing to increase the impact of their own Lung Cancer Screening programs. Dr. Kane's teaching expertise has been recognized through the receipt of numerous teaching awards including the Mary F. Lindback Award for Distinguished Teaching. In 1997, Dr. Kane was honored with the presentation of his portrait by the senior class at Jefferson Medical College. In 2011, he was recognized nationally through receipt of the Parker J. Palmer "Courage to Teach" award from the Accreditation Council on Graduate Medical Education.

Dr. Kane has twice delivered the faculty keynote address at the Sidney Kimmel Medical College Graduation Class Day (2001 and 2017). He was also a keynote speaker for white coat ceremony in 2010 at the Sidney Kimmel Medical College. In 2019, he became a Master of the American College of Physicians. While Dr. Kane is most proud of his teaching and academic accomplishments; he remains a busy clinician and cherishes interactions with patients and colleagues in managing complex pulmonary disorders. He lives in suburban Philadelphia with his wife, Jean and enjoys visiting their 4 children in Colorado, Chicago, north Jersey and New York City.

Ella A. Kazerooni, MD, MS, FACR, FSABI



Ella A. Kazerooni, MD, MS, FACR, FSABI, is a Professor of Radiology & Internal Medicine, Associate Chair for Clinical Affairs & Director of Cardiothoracic Radiology at the University of Michigan / Michigan Medicine. With a Master's degree in Clinical Research Design & Statistical Analysis, her research focuses on the development/ and evaluation of advanced imaging technologies applied to the heart and lungs, including lung cancer screening, coronary artery and aortic disease, pulmonary embolism, and diffuse lung disease. Her work in clinical and translational research earned her the University of Michigan Medical School's prestigious Clinical and Health Services Researcher of the year award. She has given over 400 lectures, nearly 300 peer-reviewed manuscripts, 30 book chapters and 4 books. She began the Radiology Service

Excellence Program at U of M, with the department achieving the highest patient satisfaction scores in the health system. She is a frequently invited speaker on the topics of patient centered care & service excellence, lung cancer screening and lung disease, and is passionate about mentoring and coaching faculty and trainees as clinicians & scientists and as leaders.

A past president of the ARRS, AUR, Society of Thoracic Radiology and the Radiology Alliance for Health Services Research, she is also an immediate past Trustee of the American Board of Radiology and has also served on the ACR Board of Chancellors.

Dr. Kazerooni is the vice Chair of the NCCN Lung Cancer Screening panel, and chairs the ACR Committee on Lung Cancer Screening including the Lung-RADS committee, worked towards the ACR Designated Lung Cancer Screening program under the CT accreditation program, and co-chairs the ACR's Lung Cancer Screening Registry (LCSR). These efforts are focused on bringing quality lung cancer screening to high risk individuals and reduce the mortality from the #1 cancer killer. Most recently, she was named the inaugural chair of the American Cancer Society's National Lung Cancer Roundtable.

Montessa Lee



Montessa Lee is a National Board Certified Teacher, Mentor Teacher, and advocate for lung cancer awareness. Montessa obtained her Bachelor of Arts in Psychology from East Carolina University, a Master of Science in Special Education from Johns Hopkins University, and is currently pursuing her Doctorate in Education at Regent University. She found her passion and purpose in educating students with exceptional needs, eventually specializing in working with students diagnosed with autism.

After being diagnosed with small cell lung cancer in 2006, Montessa chronicled her experiences, believing her experience would be a healing testimony for some beyond herself. Through her journey, her memoir *He Whispered Life* was birthed.

Through her lung cancer journey, Montessa has found that funding for research in lung cancer is inadequate given that lung cancer is the leading cancer killer. Since her diagnosis, she has pursued efforts to focus on lung cancer awareness and research.

Aurora Lucas



Aurora Lucas is a survivor and patient of NSCLC EGFR Exon 19, was diagnosed at 28 during her EdD program and while teaching as a Special Education teacher. Enduring a 2.5-month delay due to her insurance and age, Aurora is now determined to help other patients. Through Instagram and Tiktok, Aurora hopes to leverage social media to create content that is reliable and relatable in regards to figuring out how to navigate a tough medical healthcare system, and how patients can become better advocates for themselves. Aurora is currently on targeted therapy and hopes to learn more languages to be able to speak and connect to more patients and their families.

Timothy M. Merchant



Timothy M. Merchant has over twenty-five years of leadership experience in the healthcare and medical device industry. During his career, he has proudly partnered with the largest health systems in the country. Since joining RadNet (www.radnet.com) in the spring of 2021, Tim has focused on developing cancer screening networks supporting population health. He has been active in both state and federal lobbying efforts to remove cancer screening barriers. He currently serves on the Board of Directors as Executive Director for the Florida Lung Health Coalition (www.floridalunghealth.org). Before joining RadNet, Tim led National IDN partnerships for Hologic, served as Vice President of Reprocessing Sales for Medline Industries, and worked as a National Accounts Director for U.S. Surgical-Covidien. He holds a bachelor's degree from Illinois State University and post-graduate certificates from Rutgers and Northwestern Universities. He has served as lead volunteer for the Advocate Lutheran General Adult Down Syndrome Center and worked with the Northern Arizona Special Olympics.

Drew Moghanaki, MD, MPH



Drew Moghanaki, MD, MPH, is Professor and Chief of Thoracic Oncology in the UCLA Department of Radiation Oncology and co-director of the VA Greater Los Angeles Lung Precision Oncology Program.

Michelle Mollica, PhD, MPH, RN, OCN



Michelle Mollica, PhD, MPH, RN, OCN, serves as deputy director of the NCI Office of Cancer Survivorship. In this role, Dr. Mollica is responsible for developing, supporting, and promoting research efforts focused on cancer survivorship. Dr. Mollica also holds a secondary appointment as a program director in the Outcomes Research Branch (ORB) of the Healthcare Delivery Research Program, where she manages a research portfolio of grants focused on cancer survivorship and healthcare delivery across the lifecourse, from childhood through older adulthood. Dr. Mollica has served as scientific lead for several recent funding opportunity announcements focused on specific aspects of survivorship care, including primary

care, transitions in care, metastatic cancer survivorship, and informal cancer caregiving. Prior to NCI, Dr. Mollica worked clinically as an oncology nurse at Roswell Park Comprehensive Cancer Center in Buffalo, NY.

Ronald E. Myers, DSW, PhD, FSBM



Ronald E. Myers, DSW, PhD, FSBM, is a Professor and is Director of the Division of Population Science in the Department of Medical Oncology of Thomas Jefferson University and is Director of the Center for Health Decisions in the Sidney Kimmel Cancer Center of Thomas Jefferson University. His areas of expertise include patient adherence to cancer screening, physician follow-up of abnormal cancer screening test results, preference-based tailored navigation, disparities in cancer prevention and control, and shared decision making in cancer care. Dr. Myers has led numerous studies of shared decision making in genetic risk assessment, colorectal cancer screening, lung cancer screening, prostate cancer screening, multi-cancer early detection, lung cancer

treatment, prostate cancer treatment, and clinical trials participation. He is currently PI on an NCI-funded R01 that is a multi-level implementation science study on lung cancer screening across four health systems. In addition, Dr. Myers is PI of a subcontract for the Pennsylvania Department of Health CURE Award that aims to evaluate the effect of patient outreach and shared decision making on lung cancer screening in vulnerable populations. He has also co-lead a recently-completed Bristol Myers Squibb Foundation-funded project designed to develop strategies that can be used in health systems to increase lung cancer screening in vulnerable populations.

Shreya Papneja



Shreya Papneja is a third-year undergraduate student at George Washington University (GW) with an intended major in Neuroscience and a minor in Philosophy. She serves as a National Director of the American Lung Cancer Screening Initiative (ALCSI) and the President of the GW Chapter of ALCSI. Papneja is a Clinical Research Assistant in the Division of Thoracic Surgery at Massachusetts General Hospital and in the Washington Congenital Heart Program, Department of Cardiology at Children's National Hospital. She is also an intern at the Ralph Lauren Center for Cancer Prevention at the Georgetown Lombardi Comprehensive Cancer Center. Passionate about the intersection between policy, activism, and research, Papneja strives

to increase the accessibility of lung cancer screening in her community and reduce the stigma associated with lung cancer in Washington D.C., and beyond.


Manali Patel, MD, MPH, MS, FASCO



Manali Patel, MD, MPH, MS, FASCO, is an Associate Professor at Stanford in the Division of Oncology and a Staff Oncologist with a focus on thoracic oncology at the VA Palo Alto Health Care System. She is a health services researcher and directs a research program that focuses on improving equitable delivery of value-based cancer care. She uses principles of community-based participatory research in her work and is the principal investigator of multiple externally funded awards such as the California Initiative to Advance Precision Medicine, the Patient Centered outcomes Research Institute, and the National Institutes of Health. She is the Director and Founder of a Veteran Patient-Centered Care Program for the Veterans Affairs

National Oncology Program focused on improving cancer care for Veterans across the United States. Dr. Patel serves on several national committees. She was the past chair of the American Society of Clinical Oncology Health Equity Committee, serves on the American Society of Clinical Oncology Government Relations Committee, is a Cancer.Net Associate Editor for Health Equity, and the Editor-Elect for the State of Cancer Care in America. She earned her MD and Masters in Public Health at the University of North Carolina at Chapel Hill, followed by Internal Medicine Residency, Hematology and Oncology Fellowship and several research fellowships in addition to obtaining a Masters in Health Services Research at Stanford University School of Medicine.

Estelamari Rodriguez, MD, MPH



Estelamari Rodriguez, MD, MPH, is Clinical Research Lead of Thoracic Oncology and Associate Director of Community Outreach of the NCI-designated Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. She is a board certified in medical oncology and hematology. She has a special interest in the early detection of lung cancer and early phase clinical trials.

Dr. Rodriguez received her bachelor's degree from Columbia College and her medical degree from State University of New York (SUNY) Downstate College of Medicine. She completed her internal medicine residency at Columbia University's New York-Presbyterian Hospital and her medical oncology fellowship at the University of Pennsylvania. Dr. Rodriguez also has a master's degree in Public Health from the Universidad Autonoma de Madrid, Spain. She has given numerous lectures as invited speaker on issues related to lung cancer and healthcare disparities.

Priyanka Senthil



Priyanka Senthil is a researcher at the Massachusetts General Hospital in Boston, MA. Her primary clinical research focus is in the field of thoracic oncology, with a specific focus on lung cancer screening. She is the Executive Director of the American Lung Cancer Screening Initiative (ALCSI), a 501(c)(3) non-profit, which has worked with communities across all 50 US states to teach people about the importance of lung cancer screening. Ms. Senthil leads ALCSI's podcast series with lung cancer survivors and experts and has given two TEDx talks on lung cancer and lung cancer screening.

Lecia V. Sequist, MD, MPH




I have nearly 20 years of experience as a clinical and translational researcher in the field of lung cancer and early cancer detection. My currently focus is on optimizing the early detection of lung cancer and other cancers utilizing novel technologies such as circulating tumor DNA, circulating tumor cells, plasma proteomics, and radiology-based machine learning. In the earlier portion of my career I developed novel therapeutics for lung cancer patients and led translational work on resistance to targeted therapies. I have significant leadership experience across a variety of settings that give me the perspective and the expertise to contribute to a productive collaboration, including scientific writing, leading multi-institutional grants, partnering with industry, leading NCI Cooperative Group efforts, planning and teaching at continuing medical education forums, interacting with patients and patient-advocacy groups, and mentoring/sponsoring junior faculty from my own and other institutions. I am the Program Director for Cancer Early Detection and Diagnostics at MGH and am the leader of the research program in Cancer Risk, Prevention and Early Detection at the Dana-Farber/ Harvard Cancer Center.

Kathryn Taylor, PhD



Kathryn Taylor, PhD, is a Professor in the Department of Oncology at the Georgetown Lombardi Comprehensive Cancer Center in Washington DC. Dr. Taylor’s research focuses on the development and implementation of smoking cessation interventions for individuals who are at high risk for lung cancer and are eligible for lung cancer screening. She is the program lead for Lombardi’s Cancer Center Cessation Initiative (C3i) that includes a clinical program providing evidence-based tobacco treatment to patients diagnosed with cancer and hematologic conditions. Dr. Taylor earned her Ph.D. in clinical psychology from SUNY at Stony Brook and completed a postdoctoral fellowship at Memorial Sloan-Kettering Cancer Center.

Betty Tong, MD, MHS, MS



Betty Tong, MD, MHS, MS, is a tenured Associate Professor of Surgery in the Division of Cardiovascular and Thoracic Surgery at the Duke University Medical Center. Her clinical interests include minimally invasive lung surgery, chest wall resection and reconstruction, and lung cancer screening. She is a member of the NCCN Lung Cancer Screening Guidelines panel, as well as the American College of Radiology Guidelines panel for lung cancer screening imaging.

Thomas K. Varghese Jr. MD, MS, MBA, FACS, MAMSE



Thomas K. Varghese Jr. MD, MS, MBA, FACS, MAMSE, is the Chief, Section of General Thoracic Surgery at the University of Utah; Chief Value Officer (Ambulatory and Inpatient) at the Huntsman Cancer Institute; Associate Chief Medical Quality Officer at HCI; and a Professor (Tenure-track) in the Department of Surgery at the University of Utah School of Medicine. Dr. Varghese holds national leadership positions in the Society of Thoracic Surgeons, Thoracic Surgery Directors Association, American College of Surgeons, and Society of University Surgeons (SUS). He is the President-Elect of SUS.

A health services researcher whose clinical, research and operational experience are on the optimization of patient health before surgery, surgeon performance and health system outcomes, Tom helped create the American College of Surgeons Strong for Surgery program (<https://www.facs.org/quality-programs/strong-for-surgery>) and is a co-PI on the National Cancer Institute RO1-funded clinical trial on the role of Precision Exercise Prescription (PEP) for elective lung cancer surgical resection (<https://clinicaltrials.gov/ct2/show/NCT03306992>). He helped launch the podcasts “Beyond the Abstract” and “Same Surgeon, Different Light” for the STS.

In addition to his academic work, Tom’s passion is the quest to build a better world through Excellence, including DEI and social justice efforts. Dr. Varghese is a leader with a robust track record of mentoring and sponsoring medical students, residents, fellows, junior faculty, post-doctoral research graduates, and PhD students for the past 16 years, and was recently inducted as a Member of the ACS Academy of Master Surgeon Educators. He is a member of the Huntsman Cancer Institute’s Equity, Diversity, Inclusion (EDI) Governance Council and HCI’s Enterprise Leadership Council. Dr. Varghese had the honor of serving as the co-chair of the Association of Women Surgeons #HeForShe Task Force from 2017 to 2019, and served as the inaugural Chair of the Society of University Surgeons Justice.Equity.Diversity.Inclusion (J.E.D.I) Committee (Taskforce Chair 2019-2020; Committee Chair 2020-2023). In this role for SUS, he led the SUS Promising Leaders program for mid-career under-represented in medicine (URM) faculty, and is a co-PI of an ACS Board of Regents Innovative DEI and Anti-Racism grant that led to the development of the SUS-AAS JUMPSTART program (<https://www.sus-aas-dei.org/>).

Tom spends his free time with his family, as well as actively engaging on social media.

Twitter: @tomvarghesejr

Linked-In: www.linkedin.com/in/tomvarghesejr

University of Utah Academic Website:

<https://healthcare.utah.edu/fad/mddetail.php?physicianID=u6001828>

Richard Wender, MD



Richard Wender, MD, has dedicated his career to leading medical and public health efforts that strive to improve the quality of primary care and improve population health. He is currently Chair and Professor of the Department of Family Medicine and Community Health, in the Perelman School of Medicine at the University of Pennsylvania. Dr. Wender spent 33 years in the Department of Family and Community Medicine at Thomas Jefferson University, including 12 years as the Alumni Professor and Chair of the Department. From 2013 to 2020, Dr. Wender served as the first Chief Cancer Control Officer of the American Cancer Society. He helped launch a national

initiative to achieve 80% colorectal cancer screening rates in every community and a campaign to increase HPV vaccination rates. Dr. Wender has continuously advocated for the importance of preventive care and for the creation of an effective bridge between primary care and public health.

J. Lee Westmaas, PhD



My research focuses on promoting cessation of tobacco use (including ENDS) using a social ecological framework. My research has included investigations of the impact of policy and environmental factors, and community and individual-level factors such as social support (e.g., social control, social isolation, perceived availability of social support for quitting), personality, and emotional states (e.g., depression) on tobacco cessation. I also examine how the impact of these factors on cessation are moderated by sociodemographic characteristics such as gender, socioeconomic status and race/ethnicity. I use results from my research to develop smoking-cessation interventions that are targeted or tailored to individuals or

groups that experience tobacco-related disparities, and that can be disseminated at the population level using available digital technologies (e.g., smartphone apps, emails, etc.). Recently I have expanded the focus of my research to include investigating the prevalence of and predictors of cannabis use, its relationship to quitting cigarette smoking, its association with psychological variables such as anxiety, depression, and overall well-being, and with physical health and medical and cancer endpoints.

Ignacio I. Wistuba, MD



Ignacio I. Wistuba, MD, is professor and chair of the Department of Translational Molecular Pathology with joint appointment in the Department of Thoracic/Head and Neck Cancer Medical Oncology, and Co-Director, Khalifa Institute for Personalized Cancer Therapy (IPCT), at the University of Texas MD Anderson Cancer Center in Houston. Dr. Wistuba serves as leader of the Pathology Core Facility of the MD Anderson Cancer Comprehensive Center Support Grant (CCSG) and director of the UT Lung Specialized Programs of Research Excellence (SPORE) Tissue Bank. He is co-director of the MD Anderson Adaptive Patient-Oriented Longitudinal Learning and Optimization (APOLLO) Platform. At national level, he is director of the Eastern

Cooperative Oncology Group (ECOG), and the American College of Radiology Imaging Network (ACRIN) Central Biorepository and Pathology Facility (EA CBPF), pathologist for the Lung Cancer

Committee of SWOG Cancer Research Network., and leading pathologist of the US Lung Cancer Mutation Consortium. Dr Wistuba's major research interest is the elucidation of the molecular abnormalities involved in the pathogenesis and progression of lung cancer and other solid tumors. His research interests also include identifying new molecular targets, validating biomarkers for targeted therapy and immunotherapy clinical trials. Dr Wistuba has published over 800 papers in peer-reviewed journals and several book chapters. He is associate editor of *Annals of Oncology* and senior editor of *Cancer Prevention Research*. He serves as member of board of directors of the International Association for the Study of Lung Cancer (IASLC).

Douglas E. Wood, MD, FACS, FRCSEd



Douglas E. Wood, MD, FACS, FRCSEd, is The Henry N. Harkins Professor and Chair of the Department of Surgery at University of Washington. Prior to that he was Professor and Endowed Chair in Lung Cancer Research in the Department of Surgery at the University of Washington, where he was the Chief of the Division of Cardiothoracic Surgery. Dr. Wood received his undergraduate and medical degrees from Harvard University and trained in General Surgery and Cardiothoracic Surgery at the Massachusetts General Hospital in Boston.

Dr. Wood is a world leader in thoracic surgery and thoracic oncology. He is past president of the Society of Thoracic Surgeons, Western Thoracic Surgical Association, and Seattle Surgical Society, previously serving as Director of the American Board of Thoracic Surgery and Chair of the ACGME Thoracic RRC. Dr. Wood is currently the president of the Thoracic Surgery Foundation and president of the Cardiothoracic Surgery Network (CTSNet). He serves as the chair of the National Comprehensive Cancer Network (NCCN) Lung Cancer Screening Panel, vice-chair of the NCCN Non-Small Cell Lung Cancer Panel, and vice-chair of the American Cancer Society National Lung Cancer Roundtable.